CN113101530A - System for activating vitreous cavity implanted light emitting diode through wireless charging - Google Patents
System for activating vitreous cavity implanted light emitting diode through wireless charging Download PDFInfo
- Publication number
- CN113101530A CN113101530A CN202110400998.4A CN202110400998A CN113101530A CN 113101530 A CN113101530 A CN 113101530A CN 202110400998 A CN202110400998 A CN 202110400998A CN 113101530 A CN113101530 A CN 113101530A
- Authority
- CN
- China
- Prior art keywords
- emitting diode
- light emitting
- wireless charging
- activating
- vitreous cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003213 activating effect Effects 0.000 title claims abstract description 16
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 18
- 239000007943 implant Substances 0.000 claims abstract description 16
- 239000011241 protective layer Substances 0.000 claims abstract description 14
- 238000005516 engineering process Methods 0.000 claims abstract description 9
- 230000005674 electromagnetic induction Effects 0.000 claims abstract description 7
- 210000001508 eye Anatomy 0.000 claims abstract description 6
- 238000004891 communication Methods 0.000 claims description 4
- -1 polyethylene acrylate Polymers 0.000 claims description 3
- 210000000707 wrist Anatomy 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 24
- 230000001613 neoplastic effect Effects 0.000 abstract description 7
- 101100462193 Danio rerio opn4a gene Proteins 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000002870 angiogenesis inducing agent Substances 0.000 abstract description 5
- 230000001772 anti-angiogenic effect Effects 0.000 abstract description 5
- 210000003994 retinal ganglion cell Anatomy 0.000 abstract description 5
- 206010025421 Macule Diseases 0.000 abstract description 4
- 239000000049 pigment Substances 0.000 abstract description 2
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 206010064930 age-related macular degeneration Diseases 0.000 description 7
- 208000002780 macular degeneration Diseases 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000006439 vascular pathology Effects 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/0079—Methods or devices for eye surgery using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
- H02J50/10—Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
Abstract
The invention provides a system for activating a vitreous cavity implantable light emitting diode through wireless charging, which comprises: the eyeball implant is implanted into the vitreous cavity of an eyeball and comprises an outer protective layer, an electric energy receiving and converting device and a light emitting diode; the electric energy receiving and converting device is positioned in the outer protective layer and comprises a receiving coil, a receiving circuit and a charging circuit; the light emitting diode is positioned inside the outer protective layer and is electrically connected with the charging circuit; the wavelength of light emitted by the light emitting diode is 470-490 nanometers; and the wireless power supply device is a wearable device and is used for supplying power to the electric energy receiving and converting device through an electromagnetic induction wireless charging technology. The invention uses the nano light wave emitted by the light emitting diode implanted into the eye to radiate opn4 pigment positive retinal ganglion cells near the macula, opn4 absorbs ultraviolet rays with the wavelength of about 480nm and activates and releases anti-angiogenic factors to melt the neoplastic blood vessels of the fundus; the equipment used for treatment is simple and convenient to operate, the treatment continuity and stability are good, and postoperative diseases are not easy to relapse.
Description
Technical Field
The invention relates to the technical field of medical engineering, in particular to a system for activating a vitreous cavity implanted light emitting diode through wireless charging.
Background
Age-related macular degeneration (AMD) severely threatens the vision of the elderly. Wet AMD in AMD presents Choroidal Neovascularization (CNV) at the macula, causing structural and functional damage to the Retinal Pigment Epithelium (RPE). The current treatment for AMD is mainly the frequent intravitreal injection of anti-VEGF (vascular permeability factor) drugs. Although vascular lesions may be prevented to some extent, continuous VEGF antibody injection results in a decrease in VEGF titer and production of autoantibodies against VEGF antibodies, which down-regulates therapeutic efficacy. When the drug is not injected any more, the disease tends to recur.
Disclosure of Invention
Aiming at the defects of the existing antibody medicine technology and curative effect, the invention provides a system for activating a vitreous cavity implanted light emitting diode based on a wireless near-field coil, which aims to solve the technical problems that the potential inherent degeneration process of the disease cannot be prevented and the disease is easy to relapse after the injection of the medicine is stopped when the anti-vascular permeability factor medicine is injected into the vitreous cavity for treating age-related macular degeneration in the prior art.
The invention adopts the technical scheme that a system for activating a vitreous cavity implanted light emitting diode through wireless charging comprises:
the eyeball implant is implanted into the vitreous cavity of an eyeball and comprises an outer protective layer, an electric energy receiving and converting device and a light emitting diode;
the electric energy receiving and converting device is positioned in the outer protective layer and comprises a receiving coil, a receiving circuit and a charging circuit;
the light emitting diode is positioned inside the outer protective layer and is electrically connected with the charging circuit; the wavelength of light emitted by the light emitting diode is 470-490 nanometers;
and the wireless power supply device is a wearable device and is used for supplying power to the electric energy receiving and converting device through an electromagnetic induction wireless charging technology.
In one implementation, the outer protective layer is a variable polyethylene acrylate.
In one implementation, a wireless power supply includes a power management circuit, a transmit circuit; the transmitting circuit is provided with a transmitting coil.
In one implementation manner, the transmitting coil and the receiving coil are NFC near-field communication coils.
In an implementation manner, the wireless power supply device further includes a timing reminder, and the timing reminder is electrically connected to the power management circuit.
In one implementation, the wearable device includes a helmet, an eye shield, a wrist band.
In one implementation, the power input of the wearable device is mains power or a battery, and a switch is provided.
In one implementation, the eyeball implant has a size of 2-3mm, the power receiving and converting device is a micro-electromechanical device, and the light emitting diode is a mu LED.
In one implementation, the light emitting diode emits light having a wavelength of 480 nm.
According to the technical scheme, the beneficial technical effects of the invention are as follows:
the micro light-emitting diode is implanted into the eye, the micro light-emitting diode is activated from the outside when treatment is needed through an electromagnetic induction wireless charging technology, opn4 positive retinal ganglion cells near the macula are activated by means of light waves with 470-490 nanometer wavelength, and anti-angiogenic factors are released through activation to ablate the fundus neoplastic vessels. The treatment process has simple equipment and convenient operation, the continuity and the stability of the treatment by using the system are good, and the disease is not easy to relapse after the treatment.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. Throughout the drawings, like elements or portions are generally identified by like reference numerals. In the drawings, elements or portions are not necessarily drawn to scale.
FIG. 1 is a block diagram of a system according to embodiment 1 of the present invention;
FIG. 2 is a schematic view of an eyeball implant implanted in a vitreous cavity according to example 1 of the present invention;
FIG. 3 is a graph showing the vasosuppressive effect of example 1 after the activation of the release of anti-angiogenic factors;
FIG. 4 is a schematic view showing the inhibitory effect on vascular pathology according to example 1 of the present invention;
fig. 5 is a system block diagram of embodiment 2 of the present invention.
Reference numerals:
1-eyeball implant, 2-vitreous cavity and 3-needle tube sleeve.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to the accompanying drawings. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
The embodiment provides a system for activating a vitreous cavity implantable light emitting diode through wireless charging, as shown in fig. 1 and fig. 2, specifically as follows:
the eyeball implant comprises an outer protective layer, an electric energy receiving and converting device and a light emitting diode, the whole size of the eyeball implant is small, the shape is not limited, for example, the eyeball implant is spherical, and the diameter of the sphere is 2-3 mm. The outer protective layer is used as the outermost layer of the eyeball implant, the variable polyethylene acrylate is selected, and the electric energy receiving and converting device and the light emitting diode are arranged inside the outer protective layer. The electric energy receiving and converting device is a micro-electromechanical device manufactured by a micro-assembly process; the light emitting diode is a micro Light Emitting Diode (LED), wherein the micro LED is an LED array with the single size smaller than 50 μm, and the wavelength of light waves emitted by the light emitting diode is 470-490 nanometers. The eyeball implant 1 can be implanted into the vitreous cavity 2 through the needle cannula sleeve 3 and can be spread into a thin sheet shape after being implanted.
The electric energy receiving and converting device comprises a receiving coil, a receiving circuit and a charging circuit, wherein the charging circuit is electrically connected with the mu LED. The wireless power supply device comprises a power supply management circuit and a transmitting circuit; the transmitting circuit is provided with a transmitting coil. The wireless power supply device supplies power to the electric energy receiving and converting device by using an electromagnetic induction wireless charging technology. The electromagnetic induction wireless charging technology is a mature technology in the prior art, and in a specific implementation mode, a receiving coil, a receiving circuit and a charging circuit of an electric energy receiving and converting device are provided; the circuit principle and the specific form of the realization of the power management circuit, the transmitting circuit and the transmitting coil of the wireless power supply device are not limited, and any mode which can be realized in the prior art can be selected; for example, the following steps are carried out: and the transmitting coil and the receiving coil adopt NFC near field communication coils.
The system of this embodiment can supply hospital medical personnel or patient to use by oneself, and for convenient operation, wireless power supply unit designs into wearable equipment, including helmet, eye-shade, wrist strap. The wearable device inputs commercial power or a battery, and a switch is arranged to control the wearable device to start and stop working. The battery can be a polymer lithium battery, the application scene can be better expanded by using the battery, and the whole system can work under the condition of no external power supply.
The working principle of example 1 is explained in detail below:
firstly, an ophthalmologist implants an eyeball implant into a vitreous cavity of an eyeball of a patient, and at the moment, an electric energy receiving and converting device and a light emitting diode in the eyeball implant are not started to work. The eyeball implant does not need to be taken out after being implanted, and the vision is not interfered.
After the operation, when the ophthalmologist confirms that the operation is successful and the next treatment for AMD can be carried out, the patient uses the wearable device to charge the electric energy receiving and converting device through the wireless power supply device. Specifically, because of the operating distance of NFC near field communication coil is 10cm, when wearable equipment was helmet, eye-shade, the patient can wear helmet, eye-shade on the head, opens the switch, for wireless power supply device circular telegram. The power management circuit and the transmitting circuit of the wireless power supply device start to work, and energy is transmitted to the receiving coil of the electric energy receiving and converting device through the transmitting coil. The electric energy receiving and converting device supplies power to the mu LED through the receiving circuit and the charging circuit. The mu LED can emit light with the wavelength of 470-490 nanometers after being electrified, and the light carries out photosensitive control radiation on retinal opn4 (opsin) type retinal ganglion cells, activates and releases anti-vascular factors, and carries out ablation on the bottom of the eye neoplastic vessels (choroid neovascularization).
The treatment time for ablating blood vessels is about 3-5 minutes, and a plurality of treatments can be carried out every day, such as 3-5 times, so as to achieve better treatment effect. After a treatment period, the patient goes to a hospital for examination, and the treatment can be finished when the neoplastic blood vessels are basically ablated. After the neoplastic blood vessel is ablated, AMD is not easy to relapse, and the treatment effect is better. If the subsequent degeneracy and the neoplastic blood vessel are regenerated, the system of the embodiment is used again for treatment, and the operation is also simple and easy.
In a specific embodiment, the wavelength of light emitted by the μ LED is preferably 480 nm. The 480nm light wave has obvious light activation characteristic to opn4 pigment type retinal ganglion cells. Fig. 3 is a schematic diagram showing the vascular inhibitory effect of the vascular network after the activation and release of the anti-angiogenic factor under the irradiation of light waves with wavelengths of 480nm (fig. 3a) and 480nm (fig. 3b), respectively. Fig. 4 is a schematic diagram of the effect of inhibiting vascular pathology, where fig. 4a corresponds to 480nm lightwave radiation, and fig. 4b corresponds to 480nm lightwave radiation, and it can be clearly seen from the diagram that the effect of 480nm lightwave radiation is significant, and the effect of 480nm lightwave radiation is not significant.
According to the technical scheme provided by the embodiment, the micro light-emitting diode is implanted into the eye, the micro light-emitting diode is activated from the outside when treatment is needed through an electromagnetic induction wireless charging technology, and the opn4 positive retinal ganglion cells near the macula are irradiated by light waves with the wavelength of 470-490 nanometers (preferably 480 nanometers) to activate and release anti-angiogenic factors so as to ablate the fundus neoplastic blood vessels. The treatment process adopts simple equipment and is convenient to operate, the continuity and the stability of treatment by using the system are good, and diseases are not easy to relapse after treatment.
Example 2
In actual use, the treatment time of each time should be controlled to 3-5 minutes. To solve the problem of controlling the treatment duration, the method is further optimized on the basis of the embodiment 1, and as shown in fig. 5, the following technical scheme is adopted:
the wireless power supply device further comprises a timing reminder, and the timing reminder is electrically connected with the power management circuit.
The timing reminder comprises a timing chip, a control chip and a buzzer. When the switch of the wearable device is turned on, the power management circuit starts working, the timing chip starts timing, and when the time reaches 2-4 minutes, the control chip controls the buzzer to give an alarm in a sound mode. After the medical staff or the patient hears the alarm prompt, the switch of the wearable device can be closed, the power supply of the wireless power supply device to the electric energy receiving and converting device is stopped, the mu LED does not emit light after about 1 minute, and the treatment is finished.
Through the technical scheme of this embodiment, can remind medical personnel or patient to control treatment time, obtain better treatment.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (9)
1. A system for activating a vitreous cavity implantable light emitting diode by wireless charging, comprising:
the eyeball implant is implanted into the vitreous cavity of an eyeball and comprises an outer protective layer, an electric energy receiving and converting device and a light emitting diode;
the electric energy receiving and converting device is positioned in the outer protective layer and comprises a receiving coil, a receiving circuit and a charging circuit;
the light emitting diode is positioned inside the outer protective layer and is electrically connected with the charging circuit; the wavelength of the light wave emitted by the light emitting diode is 470-490 nanometers;
and the wireless power supply device is a wearable device and is used for supplying power to the electric energy receiving and converting device through an electromagnetic induction wireless charging technology.
2. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 1, wherein: the outer protective layer is made of variable polyethylene acrylate.
3. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 1, wherein: the wireless power supply device comprises a power management circuit and a transmitting circuit; and a transmitting coil is arranged in the transmitting circuit.
4. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 3, wherein: and the transmitting coil and the receiving coil are NFC near field communication coils.
5. The system for activating a vitreous chamber implantable Light Emitting Diode (LED) by wireless charging as claimed in claim 3, wherein said wireless power supply further comprises a timing reminder, said timing reminder being electrically connected to said power management circuit.
6. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 1, wherein: the wearable device comprises a helmet, an eye patch and a wrist strap.
7. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 6, wherein: the electric energy input of wearable equipment is commercial power or battery to be equipped with the switch.
8. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 1, wherein: the size of the eyeball implant is 2-3mm, the electric energy receiving and converting device is a micro-electromechanical device, and the light emitting diode is a mu LED.
9. The system for activating a vitreous cavity implantable Light Emitting Diode (LED) by wireless charging according to claim 1, wherein: the wavelength of light wave emitted by the light emitting diode is 480 nanometers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110400998.4A CN113101530B (en) | 2021-04-14 | 2021-04-14 | System for activating vitreous cavity implanted light emitting diode through wireless charging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110400998.4A CN113101530B (en) | 2021-04-14 | 2021-04-14 | System for activating vitreous cavity implanted light emitting diode through wireless charging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113101530A true CN113101530A (en) | 2021-07-13 |
| CN113101530B CN113101530B (en) | 2022-09-30 |
Family
ID=76716907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110400998.4A Expired - Fee Related CN113101530B (en) | 2021-04-14 | 2021-04-14 | System for activating vitreous cavity implanted light emitting diode through wireless charging |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113101530B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582156A (en) * | 2001-11-09 | 2005-02-16 | 眼科技术药物公司 | Methods for treating ocular neovascular diseases |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20060235493A1 (en) * | 2005-04-14 | 2006-10-19 | Dotson Robert S | Ophthalmic phototherapy device and associated treatment method |
| US20170358942A1 (en) * | 2016-06-13 | 2017-12-14 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus for wireless biomedical device charging |
| US20180243083A1 (en) * | 2015-09-03 | 2018-08-30 | Elenza, Inc. | Rechargeable intraocular implant |
| CN109789011A (en) * | 2016-10-03 | 2019-05-21 | 加州理工学院 | Radioluminescence phototherapy eye equipment |
| CA3121279A1 (en) * | 2018-11-30 | 2020-06-04 | Joseph J.K. MA | Ocular systems, devices, and methods |
-
2021
- 2021-04-14 CN CN202110400998.4A patent/CN113101530B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582156A (en) * | 2001-11-09 | 2005-02-16 | 眼科技术药物公司 | Methods for treating ocular neovascular diseases |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20060235493A1 (en) * | 2005-04-14 | 2006-10-19 | Dotson Robert S | Ophthalmic phototherapy device and associated treatment method |
| US20180243083A1 (en) * | 2015-09-03 | 2018-08-30 | Elenza, Inc. | Rechargeable intraocular implant |
| US20170358942A1 (en) * | 2016-06-13 | 2017-12-14 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus for wireless biomedical device charging |
| CN109789011A (en) * | 2016-10-03 | 2019-05-21 | 加州理工学院 | Radioluminescence phototherapy eye equipment |
| CA3121279A1 (en) * | 2018-11-30 | 2020-06-04 | Joseph J.K. MA | Ocular systems, devices, and methods |
Non-Patent Citations (1)
| Title |
|---|
| 方肖云: "视网膜假体的研究进展", 《国外医学.眼科学分册》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113101530B (en) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10583307B2 (en) | Heating device and method of use | |
| RU2567263C2 (en) | System for delivery of electromagnetic radiation in subject's eyeball | |
| CN105120809B (en) | Use the heating device of heat-producing chemical reaction | |
| CN111954556B (en) | Controllable phototherapy contact lens for ocular phototherapy | |
| CN104288914B (en) | Intelligent laser therapy apparatus for treating onychomycosis | |
| CN106413644B (en) | Device for medical treatment of the sclera | |
| US20100198316A1 (en) | Intracranial Red Light Treatment Device For Chronic Pain | |
| US20150217129A1 (en) | System and method for therapeutic management of ocular hypertension | |
| CN105073190A (en) | Medical apparatus, system and method | |
| US20100305666A1 (en) | Induction device for photodynamic therapy and diagnosis | |
| US7441899B2 (en) | Panretinal laser fundus contact lens | |
| CN113101530B (en) | System for activating vitreous cavity implanted light emitting diode through wireless charging | |
| US11027144B2 (en) | Laser therapy for at least one of grade III and grade IV capsular contracture | |
| Cox | Introduction to laser-tissue interactions | |
| CN108671415B (en) | Medical optical fiber and laser therapeutic apparatus | |
| CN105520806A (en) | Handheld cross-linking therapeutic system for ophthalmological department | |
| CN206214267U (en) | A kind of lamp guide and hand-held crosslinking treatment system | |
| WO2021113486A1 (en) | Systems, implantable devices and methods for vision related stimulation | |
| CA3030483A1 (en) | Process for providing protective therapy for biological tissues or fluids | |
| KR102185926B1 (en) | Eye disease treatment device using pulsed electromagnetic field | |
| CN108635044B (en) | Laser therapeutic instrument | |
| US20110190747A1 (en) | Disposable led/laser catheter | |
| Zharov et al. | Optoelectronic microdevices for combined phototherapy | |
| US20220409921A1 (en) | Transcranial stimulator for rehabilitation based on photobiomodulation mechanism | |
| Xue et al. | Battery-Free Optoelectronic Patch for Photodynamic and Light Therapies in Treating Bacteria-Infected Wounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220930 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |